Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART plus dual long-acting HIV broadly neutralizing antibodies during primary HIV-1 infection
2021-003040-25Phase 2Active
- Sponsor
- Inserm-ANRS
- Start
- Oct 2021
- Modality
- Anti-infectious Disease mAbs → Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of Teropavimab and zinlirvimab in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Inserm-ANRS. Started Oct 2021; status: active.
02
Drugs
Teropavimabzinlirvimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2021-003040-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003040-25.